Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX Plus Regorafenib in Esophagogastric Cancer
NCT01913639Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2013
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in esophageal cancer, gastric cancer (GC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2013; status: completed.
02
Drugs
regorafenib
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT01913639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01913639.